• 1
    Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a ‘prima ballerina’. Thromb Haemost 1995; 74: 717.
  • 2
    Butenas S, Mann KG. Blood coagulation. Biochemistry (Moscow) 2002; 67: 312.
  • 3
    Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 13819.
  • 4
    Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 385864.
  • 5
    Hedner U. Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000; 26: 3636.
  • 6
    Monroe DM, Roberts HR. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement. Arterioscler Thromb Vasc Biol 2003; 23: 89.
  • 7
    Mann KG, Butenas S. Response: mechanism of action of high-dose factor VIIa. Arterioscler Thromb Vasc Biol 2003; 23: 10.
  • 8
    Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 13819.
  • 9
    Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 115860.
  • 10
    Butenas S, Brummel KE, Paradis SG, Mann KG. Influence of factor VIIa and phospholipids on coagulation in ‘acquired’ hemophilia. Arterioscler Thromb Vasc Biol 2003; 23: 1239.
  • 11
    Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1: 1129.
  • 12
    Eller P, Pechlaner C, Weidermann CJ. Ineffective off-label use of recombinant activated factor VII in a case of bone marrow transplantation-related gastrointestinal bleeding. Thrombosis J 2006; 4: 1.
  • 13
    Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41: 359.
  • 14
    Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 2001; 98: 135838.
  • 15
    Persson E, Nielsen LS, Olsen OH. Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. Biochemistry 2001; 40: 32516.
  • 16
    Persson E, Bak H, Olsen OH. Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity. J Biol Chem 2001; 276: 291959.
  • 17
    Persson E, Bak H, Ostergaard A, Olsen OH. Augmented intrinsic activity of factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J 2004; 379: 497503.
  • 18
    Tranholm M, Kristensen K, Kristenen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 361520.
  • 19
    Thim L, Bjoern S, Christensen M, Nicolaisen EM, Lund-Hansen T, Pedersen AH, Hedner U. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 778593.
  • 20
    Rao LVM, Williams T, Rapaport SI. Studies of the activation of factor VII bound to tissue factor. Blood 1996; 87: 373848.
  • 21
    Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octylglucoside. Biochemistry 1981; 20: 83340.
  • 22
    Rao LVM, Robinson T, Hoang AD. Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: a kinetic study. Thromb Haemost 1992; 67: 6549.
  • 23
    Rao LVM. Characterization of anti-tissue factor antibody and its use in immunoaffinity purification of human tissue factor. Thromb Res 1988; 51: 37384.
  • 24
    Pendurthi UR, Rao LVM, Williams JT, Idell S. Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. Blood 1999; 94: 57986.
  • 25
    Iakhiaev A, Ruf W, Rao LVM. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Thromb Haemost 2001; 85: 45863.
  • 26
    Rao LVM, Ruf W. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor. Biochemistry 1995; 34: 1086771.
  • 27
    Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 5427.
  • 28
    Rao LVM, Rapaport SI, Lorenzi M. Enhancement of human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 1988; 71: 7916.
  • 29
    Rao LVM, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 26007.
  • 30
    Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 1219.
  • 31
    Marcum JA, Atha DH, Fritze LMS, Nawroth P, Stern D, Rosenberg RD. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycans. J Biol Chem 1986; 261: 750717.
  • 32
    Rosenberg RD, Bauer K. The heparan sulphate-antithrombin pathway: a natural anticoagulant mechanism of the blood vessel wall: a natural anticoagulant mechanism of the blood vessel wall. In: Van HinsberghVWM, ed. Vascular Control of Hemostasis. New York: Harwood Academic Publishers, 1996: 3971.
  • 33
    Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol 2004; 41: 8992.
  • 34
    Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6: S7S13.
  • 35
    Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 1992; 267: 87682.
  • 36
    Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 38793.
  • 37
    Stern DM, Nawroth PP, Kisiel W, Handley D, Drillings M, Bartos J. A coagulation pathway on bovine aortic segments leading to generation of factor Xa and thrombin. J Clin Invest 1984; 74: 191021.
  • 38
    Rodgers GM, Shuman MA. Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci U S A 1983; 80: 70015.
  • 39
    Stern D, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U S A 1985; 82: 25237.
  • 40
    Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 76770.
  • 41
    Rao LVM, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990; 75: 106973.
  • 42
    Oliver JA, Monroe DM, Church FC, Roberts HR, Hoffman M. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 2002; 100: 53946.
  • 43
    Butenas S, Branda RF, Veer C, Cawthern KM, Mann K. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 6607.